November 2, 2022

Real-world research show the tolerability and effectiveness of trifluridine and tipiracil combined with bevacizumab for the treatment of patients with refractory metastatic colorectal cancer.

"We should continue to see steady gains in new targets and improvements in our targeted therapies that make these options available for an ever-larger subgroup of patients with non–small cell lung cancer who can derive longer duration of benefit from additional lines of treatment," says H. Jack West, MD.

In a phase 1 study, a peptide conjugated vaccine showed potent immunogenicity and was able to induce functional T-cell responses in almost all vaccinated patients with HPV16-positive premalignancies.

There was a potential antitumor signal observed with NGM120 in combination with chemotherapy, according to Andrew E. Hendifar, MD.

Canakinumab, spartalizumab, gemcitabine, and nab-paclitaxel in patients with metastatic pancreatic cancer was shown to be safe and tolerable in a phase 2 clinical trial.

In an interview , Ali Zaidi, MD, discussed how the treatment landscape for patients with esophageal cancer has evolved over previous years and what research aims to look at in the near future.

Advances in thyroid cancer to date hold promise for other orphan cancers with analogous alterations, on which we might bring to bear agents that will have similar effects.